(S (NP-SBJ (JJ Alpha-lipoic) (NN acid)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ potent) (NN inhibitor)) (PP (IN of) (NP (NP (NN NF-kappa) (NN B) (NN activation)) (PP (IN in) (NP (JJ human) (NN T) (NNS cells))))))) (. .))
(S (NP-SBJ (NP (VBN Acquired) (NN immunodeficiency) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NN AIDS)) (-RRB- -RRB-))) (VP (VBZ results) (PP (IN from) (NP (NP (NN infection)) (PP (IN with) (NP (NP (DT a) (JJ human) (NN immunodeficiency) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HIV)) (-RRB- -RRB-))))))) (. .))
(S-COOD (S (NP-SBJ (NP (DT The) (NP (NP (JJ long) (JJ terminal) (NN repeat)) (PRN (-LRB- -LRB-) (NP (NN LTR)) (-RRB- -RRB-))) (NN region)) (PP (IN of) (NP (NN HIV) (JJ proviral) (NN DNA)))) (VP (VBZ contains) (NP (NP (VBG binding) (NNS sites)) (PP (IN for) (NP (NP (JJ nuclear) (NN factor) (NN kappa) (NN B)) (PRN (-LRB- -LRB-) (NP (NN NF-kappa) (NN B)) (-RRB- -RRB-))))))) (, ,) (CC and) (S (NP-SBJ-1 (DT this) (JJ transcriptional) (NN activator)) (VP (VBZ appears) (S (NP-SBJ (-NONE- *-1)) (VP (TO to) (VP (VB regulate) (NP (NN HIV) (NN activation))))))) (. .))
(S (NP-SBJ (JJ Recent) (NNS findings)) (VP (VBP suggest) (NP (NP (DT an) (NN involvement)) (PP (IN of) (NP (NP (JJ reactive) (NN oxygen) (NNS species)) (PRN (-LRB- -LRB-) (NP (NN ROS)) (-RRB- -RRB-)))) (PP (IN in) (NP (NP (NN signal) (NN transduction) (NNS pathways)) (VP (VBG leading) (PP (TO to) (NP (NN NF-kappa) (NN B) (NN activation)))))))) (. .))
(S (NP-200 (DT The) (JJ present) (NN study)) (VP (VBD was) (VP (VBN based) (NP (-NONE- *-200)) (PP (IN on) (NP (NNS reports) (SBAR (IN that) (S-COOD (S (NP-SBJ (NP (NNS antioxidants)) (SBAR (WHNP-2 (WDT which)) (S (NP-SBJ (-NONE- *T*-2)) (VP (VBP eliminate) (NP (NN ROS)))))) (VP (MD should) (VP-COOD (VP (VB block) (NP-3 (NP (DT the) (NN activation)) (PP (IN of) (NP (NN NF-kappa) (NN B))))) (CC and) (VP (ADVP (RB subsequently)) (NP=3 (NN HIV) (NN transcription)))))) (, ,) (CC and) (RB thus) (S (NP-SBJ-4 (NNS antioxidants)) (VP (MD can) (VP (VB be) (VP (VBN used) (NP (-NONE- *-4)) (PP (IN as) (NP (NP (JJ therapeutic) (NNS agents)) (PP (IN for) (NP (NN AIDS))))))))))))))) (. .))
(S (NP-SBJ-5 (NP (NN Incubation)) (PP (IN of) (NP (NP (NN Jurkat) (NN T) (NNS cells)) (PRN (-LRB- -LRB-) (NP (QP (CD 1) (CC x) (CD 10-LRB-6-RRB-)) (NNS (ml cells))) (-RRB- -RRB-)))) (PP (IN with) (NP (DT a) (JJ natural) (NN thiol) (ADJP-COOD (ADJP (NN antioxidant)) (, ,) (ADJP (JJ alpha-lipoic))) (NN acid))) (, ,) (PP (JJ prior) (TO to) (NP (NP (DT the) (NN stimulation)) (PP (IN of) (NP (NNS cells)))))) (VP (VBD was) (VP (VBN found) (S (NP-SBJ (-NONE- *-5)) (VP (TO to) (VP (VB inhibit) (NP (NP (NN NF-kappa) (NN B) (NN activation)) (VP (VBN induced) (NP (-NONE- *)) (PP-COOD (PP (IN by) (NP (NP (NN tumor) (NN necrosis) (NN factor-alpha)) (PRN (-LRB- -LRB-) (NP (CD 25) (NN (ml ng))) (-RRB- -RRB-)))) (CC or) (PP (IN by) (NP (NP (NN phorbol) (NN 12-myristate) (NN 13-acetate)) (PRN (-LRB- -LRB-) (NP (CD 50) (NN (ml ng))) (-RRB- -RRB-)))))))))))) (. .))
(S-COOD (S (NP-SBJ-6 (NP (DT The) (JJ inhibitory) (NN action)) (PP (IN of) (NP (JJ alpha-lipoic) (NN acid)))) (VP (VBD was) (VP (VBN found) (S (NP-SBJ (-NONE- *-6)) (VP (TO to) (VP (VB be) (ADJP-PRD (RB very) (JJ potent)) (SBAR (IN as) (S (NP-SBJ-7 (QP (RB only) (CD 4)) (NN mM)) (VP (VBD was) (VP (VBN needed) (NP (-NONE- *-7)) (PP (IN for) (NP (DT a) (JJ complete) (NN inhibition))))))))))))) (, ,) (IN whereas) (S (NP-SBJ-8 (CD 20) (NN mM)) (VP (VBD was) (VP (VBN required) (NP (-NONE- *-8)) (PP (IN for) (NP (NN N-acetylcysteine)))))) (. .))
(S (NP-SBJ (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (JJ alpha-lipoic) (NN acid)) (VP (MD may) (VP (VB be) (ADJP-PRD (JJ effective)) (PP (IN in) (NP (NN AIDS) (NNS therapeutics)))))))) (. .))
